Picture loading failed.

Anti-IL17A;TNFA therapeutic antibody (Pre-made Remtolumab biosimilar,Bispecific Dual Variable Domain IG) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Remtolumab (ABT 122) is a dual-variable domain immunoglobulin, targeting tumour necrosis factor (TNF) and interleukin-17 (IL-17), that was being developed by AbbVie, for the treatment of rheumatoid arthritis and psoriatic arthritis.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-478-1mg 1mg 3090
GMP-Bios-ab-478-10mg 10mg 21890
GMP-Bios-ab-478-100mg 100mg 148000
GMP-Bios-ab-478-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-IL17A;TNFA therapeutic antibody (Pre-made Remtolumab biosimilar,Bispecific Dual Variable Domain IG)
INN Name Remtolumab
TargetIL17A;TNFA
FormatBispecific Dual Variable Domain IG
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure4nyl:EF:AB:HL:CD/6cr1:HL;None
99% SI Structure3wd5:HL;None
95-98% SI StructureNone;None
Year Proposed2016
Year Recommended2017
CompaniesAbbott Laboratories;Abbvie
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedPsoriatic arthritis;Rheumatoid arthritis
Development TechDual Variable Domain Immunoglobulin Technology